NAMPT and breast carcinoma: To evaluate whether visfatin could activate stemness ability and self-renewal in breast cancer, MDA-MB-231 cells were treated with visfatin (0, 200, or 400 ng/mL) for 24 or 48 h (Figure 1B) while using a sphere-forming assay and calculate the sphere number (Figure 1C) and diameter (Figure 1D).